Looking ahead to 2030, our model projects BNTX could trade at an average price of $206.70, with a potential range between $155.02 and $258.37. This represents a potential 111.9% return from today's ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Is BNTX a good stock to buy? We came across a bullish thesis on BioNTech SE on r/ValueInvesting by birdflustocks. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was ...

BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data ...

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do ...

Shares of BioNTech SE BNTX are trading lower on Tuesday as the company reported mixed first-quarter financial results. The stock’s decline comes amid a broader market rally, with major indices like ...

BioNTech (BNTX) stock is in focus as the company holds talks with prospective bidders regarding plans to shutter ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...